Abstract Details

Title Impact of Spasticity on Healthcare Resource Utilisation: Results of a Cross-Sectional Study in the USA

Topic MS and Related Diseases

Presentation(s) P03 - (-)

Poster/Presentation
Number 211

Objective

Background BACKGROUND: Multiple sclerosis (MS) is a chronic, often progressive disease, frequently accompanied by functional impairment due to spasticity. It is hypothesised that as the severity of spasticity increases there is a corresponding impact on healthcare resource utilisation.

Design/Methods DESIGN/METHODS: Data were drawn from the Adelphi MS Disease Specific Programme, a cross-sectional research programme including 1641 consulting MS patients in the USA. Preliminary analysis using ANOVA with Bonferroni-corrected t-tests and Fisher's Exact Test with Bonferroni corrections established that the most appropriate split was between the mild and moderate spasticity levels. Double robust estimates (propensity scoring with weighted regression) were calculated to show the differences in healthcare resource use between patients with moderate or severe spasticity and those with no or mild spasticity. Confounding factors included Expanded Disability Severity Scale (EDSS), gender, age, body mass index, concomitant conditions, compliance and MS type.

Results RESULTS: Complete data were obtained for 718 patients. Compared with patients with no or mild spasticity, the presence of moderate or severe spasticity was associated, over 12 months, with an additional 0.41 consultations with a neurologist (p<0.05), 0.97 with an MS nurse (p<0.05) and 0.94 additional consultations with a physiotherapist (p<0.01). Across all healthcare professionals, moderate/severe spasticity was associated with a net increase of 1.49 visits over 12 months (p<0.01) and also associated with an additional 0.12 emergency room visits over the same period (p<0.05). An additional 9.9% of moderate/severe spasticity patients required a professional caregiver.

Conclusions CONCLUSIONS: MS patients with moderate or severe spasticity increase the burden on the healthcare system compared with patients who have no or mild spasticity. Therefore a therapy that specifically addresses the severity of spasticity could have a positive socio-economic impact.

Authors/Disclosures
Randall T. Schapiro, MD, FAAN PRESENTER	No disclosure on file
Daniel R. Wynn, MD (Consultants in Neurology, Ltd.)	Dr. Wynn has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mylan. Dr. Wynn has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Wynn has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Wynn has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi. Dr. Wynn has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for TEVA. The institution of Dr. Wynn has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Banner Life. Dr. Wynn has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for Biogen. The institution of Dr. Wynn has received research support from Novartis. The institution of Dr. Wynn has received research support from Sanofi. The institution of Dr. Wynn has received research support from Adamas Pharmaceutics. The institution of Dr. Wynn has received research support from EMD Serono. The institution of Dr. Wynn has received research support from Roche. Dr. Wynn has a non-compensated relationship as a Director, Consultants in Neurology Comprehensive Care Center with National MS Society that is relevant to AAN interests or activities.
Dmitri V. Lissin, MD (Scilex Holding)	Dr. Lissin has received personal compensation in the range of $500,000-$999,999 for serving as a Chief Medical Officer with Scilex Holding .
Ahmad M. Al-Sabbagh, MD (Avion Pharmaceuticals)	Dr. Al-Sabbagh has nothing to disclose.
Dennis Dietrich, MD	No disclosure on file
Eddie Jones, BA	Eddie Jones, BA has nothing to disclose.
	No disclosure on file

��ɫ��

��ɫ��